A Managed Care Evaluation of the Dyslipidemia Management Advances

ACPE UAN #:  0233-0000-17-039-H01-P

Release Date:  April 25, 2017

Expiration Date:  April 25, 2019

Activity Type:  Knowledge-based  

Credit Hours:  1.0 contact hours (0.1 CEU)

Activity Fee:  There is no fee to participate in this home study activity. 

Target Audience

This home study activity has been designed to meet the educational needs of pharmacists in managed care settings.

Activity Overview:

Over 73 million adults in the United States have dyslipidemia and are at elevated risk for atherosclerotic cardiovascular disease. In 2015, the approval of two proprotien convertase subtilisin/kexin type 9 (PCSK9) inhibitors provided new options to dramatically improve lipid profiles. However, the PCSK9 inhibitors have created unprecedented challenges for health care payers due to the specialty nature of the medications, the large potential volume of patients, and the lack of definitive guidance on the use of nonstatin therapies in the treatment of dyslipidemia. Evidence-based strategies to identify the most appropriate patients for treatment with PCSK9 inhibitors are needed to support rational use of limited healthcare resources while optimizing patient care.

This program will delve into the role of nonstatin therapies in dyslipidemia management, review outcomes related to formulary and utilization management techniques, and explore the potential impact of newer agents on patient care.

Learning Objectives 

At the completion of this activity, participants should be able to:

  1. Summarize current guidelines for the treatment of dyslipidemia, including the 2016 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies.
  2. Use current evidence to identify patient populations that are expected to derive the greatest benefit from nonstatin therapies.
  3. Describe “statin intolerance” and “statin failure” and appropriate treatment options for patients with either of these conditions.
  4. Use current data to describe the impact of newer therapies on patient care.

Schedule of Educational Activity

  • Advances in Treating Dyslipidemia: The Clinical Perspective - Seth Martin, MD, MHS, FACC
  • Advances in Treating Dyslipidemia: The Managed Care Perspective - Greg Low, RPh, PhD 

CPE Requirements:   

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live webinar activity on April 25 2017.  CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor.  Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.

System Technical Requirements/Viewing Requirements: System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities you should have a basic comfort level using a computer and navigating web sites.  View the minimum technical and system requirements for continuing education online learning activities.

As an ACPE-accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of CPE activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.

Statement of Commercial Support

This educational activity is supported by an unrestricted education grant from Amgen. 

Christine L. Cooper, PharmD
Education Program Manager
Academy of Managed Care Pharmacy
Alexandria, Virginia

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-0000-17-039-H01-P 1 Contact Hour April 25, 2017 - April 25, 2019